BioSpace News Archive

CarePredict, the leading AI-powered preventive senior care platform announced today the launch of the third generation of their smart wearable - CarePredict Tempo™ Series 3.

HiFiBiO Therapeutics, a pioneer in innovative biotherapeutics with a unique single-cell analytics platform for extensive immune profiling, today announced the formation of a Scientific Advisory Board (SAB) comprised of experts in immunology, oncology and cell therapy, as well as drug discovery and development.

Combination Broadens Company’s Global Solutions Supporting Drug Development

CARsgen Therapeutics Co. Ltd., a clinical-stage biopharmaceutical company announced that the United States Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to its investigational CT053 CAR-T cell therapy.

Castle Biosciences, Inc. announced the presentation of data supporting clinical use of the DecisionDx®-Melanoma test to inform decisions of whether to discuss or recommend the sentinel lymph node biopsy, a surgical procedure used to provide additional prognostic information.

ZyVersa Therapeutics, Inc. is pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and President, is an invited speaker at the inaugural Inflammasome Therapeutics Summit to be held in Boston on October 29-31, 2019.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced a partnership with Success TMS,

Accuray Incorporated (NASDAQ: ARAY) – Thailand’s Lopburi Cancer Hospital, a center of excellence for cancer treatment, is the first in the Asia-Pacific region to clinically use the combination of RaySearch’s treatment planning system RayStation® with Accuray’s Radixact® Treatment Delivery System.

BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Phase 3 clinical trial independent Data Safety Monitoring Board (DSMB) has completed the second, pre-specified interim analysis, of safety outcomes for the first 106 patients who received repeat dosing of NurOwn® in the Phase 3 trial for ALS patients (NCT03280056).

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that clients utilizing Inovalon’s quality improvement solution suite outperformed the entire Medicare Advantage market for the sixth year in a row, realizing an average positive increase in their Centers for Medicare & Medicaid Services (CMS) 2020 Five-Star Quality Ratings of nearly 300% greater than that of health plans not using Inovalon’s analytics.